(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 2.8% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.09%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.9%.
Bioventus's revenue in 2025 is $564,142,000.On average, 1 Wall Street analysts forecast BVS's revenue for 2025 to be $46,611,962,381, with the lowest BVS revenue forecast at $46,611,962,381, and the highest BVS revenue forecast at $46,611,962,381. On average, 1 Wall Street analysts forecast BVS's revenue for 2026 to be $49,361,040,461, with the lowest BVS revenue forecast at $49,361,040,461, and the highest BVS revenue forecast at $49,361,040,461.
In 2027, BVS is forecast to generate $51,897,633,408 in revenue, with the lowest revenue forecast at $51,897,633,408 and the highest revenue forecast at $51,897,633,408.